Résultats de la recherche

​
search
Truveta Research and collaborators Dr. Ezekiel Emanuel and Dr. Ty Gluckman explore trends in patients stopping or restarting GLP-1 medications.
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
31 janv. 2025 11h18 HE | Truveta
BELLEVUE, Wash., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has...
Truveta Research study published in JAMA Internal Medicine compares tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss
Truveta’s real-world data study comparing tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss published in JAMA Internal Medicine
08 juil. 2024 11h16 HE | Truveta
BELLEVUE, Wash., July 08, 2024 (GLOBE NEWSWIRE) -- Today Truveta announced that its comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide...
Truveta Research found that patients with overweight or obesity taking tirzepatide (Mounjaro) experienced a greater percentage change in body weight than those taking semaglutide (Ozempic) for weight loss.
Largest real-world study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss
27 nov. 2023 09h00 HE | Truveta
BELLEVUE, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide...